English Community

 View Only

Log in or create an account to engage on OVdialogue. 

Expand all | Collapse all

Zejula non brca

  • 1.  Zejula non brca

    Posted 3 days ago

    I've been taking Zejula for a few months. Reduced to 100 mg due to side effects. In my research I discovered that the fda in USA has changed prescribing guidelines to exclude non brca due to trials which show worse outcomes than for those on placebo group (June 2025).

    Also Health Canada advises that docs should inform patients re these findings.

    Mine did not. Any other experiences out there



    -------------------------------------------


  • 2.  RE: Zejula non brca

    Posted 3 days ago

    @heslopk

    I am well beyond this point but find this very interesting!!

    I have heard of successes…will be a very tough decision for those now being offered the drug.

    I wonder if we're going to get a new maintenance drug to replace this thing one. Otherwise, just move forward with standard of care chemo or a clinical trial. 

    Thanks for sharing. 

    -------------------------------------------



  • 3.  RE: Zejula non brca

    Posted 2 days ago

    @pepperbee I thought this may be of interest to you as you ponder your post chemo plan. I have no idea about this drug and it's use in Canada however as you can see from the post by  @heslopk perhaps it's an option in Canada now???? You can certainly add it to your list of questions. The Teal Sisters have learned that there is no harm in asking and definitely it's important to advocate for ourselves.

    #Treatmentandsideeffects

    -------------------------------------------



  • 4.  RE: Zejula non brca

    Posted 2 days ago

    @Alwayslearning@heslopk this is what I'm suppose to go onto next.  Will definitely ask for more info.  I feel like it's kind of a crap shot at the moment.  Others on zejula what have your experiences been?

    -------------------------------------------



  • 5.  RE: Zejula non brca

    Posted 2 days ago
    I was put on 200mg of Zejula and I was tired and hot. Went down to 100 which was ok but then found out this is not a good option for non brca people. So waiting to see if I'll be offered something else. Karen H





  • 6.  RE: Zejula non brca

    Posted 2 days ago


    Good afternoon my Teal Sister Warriors!


    I'm posting this as a response to Niraparib (Zejula) not being available for those with the BRACA 1 or BRACA 2 genetic mutation.


    I live in Alberta and have been on Niraparib for over 2 years now as maintenance treatment for HGSOC Stage 3B. I have no genetic mutations (BRACA 1 & 2 negative) and I am also HRD negative.


     The PARP Inhibitor is fully paid for by the Province, and is the only PARP that is prescribed for BRACA1 or 2 negative patients where I live. I believe that is the case in the rest of Canada, although some doctors may have different protocols and/or opinions.


    Niraparib has been a game changer for me. Following my October 2022 surgery, I was NED. Before I started chemo in January 2023, I was also NED, and after I finished chemo at the end of April 2023, I was NED and have remained NED after being on Niraparib since June 2023, My last CT was May 2025 and I am still NED.


    My bloodwork has been excellent on this PARP; my platelets have never dropped and there has never been any concern. They call me "Super Woman" or "Rock Star" at the Cancer Institute!  I am monitored monthly with labs, including CA125 and 2 other tumour markers, I see the local gynecologist every 6 months, and have a CT every 6 months. I also speak with a Cancer Nurse every 3 months.


    I take 200mg daily, at bedtime. I have been fortunate to get only a few side effects, the biggest being fatigue. Not all side effects occur at once; currently I have a very itchy scalp, which could be a side effect of another medication. I had mild mouth sores last year that went away with the help of cortisone shots. I have occasional gut issues which are manageable.


    There are a lot of horror stories out there about PARPs in general. There was a lot of hoopla a few years ago about Niraparib but that was reversed or faded into the background. Many women simply can't tolerate the drug at all, this affects up to 30%. Some have a recurrence, some need a dose reduction (300mg per day is too much for most of us!!), some have remained NED for a number of years. 


    For me, I believe that the excellent care I've received, including being on Niraparib for 2 years (1 more year to go) has kept the cancer away. It is working for me, and certainly there are stats that indicate a longer PFS on a PARP vs. not being on a PARP. 


    We are all in the same boat but with different oars. We share so many similarities with this #@*&% cancer, but we all react differently at times throughout the journey. "To Be Or Not To Be" on a PARP is very much an individual choice, and if this something you feel would be a benefit, push for it. I know finances can enter into the picture especially in the US. Have your Doctor or Cancer Centre push the manufacturer for funding. The Ovarian Cancer Research Alliance (OCRA) often helps patients secure funding. They are US-based, and the leading ovarian cancer research organization in the world! I belong to one of their weekly support groups (Canadians are welcome to join) and it has been a hige blessing in my life.


    I'll get off my Niraparib Soap Box now, LOL! I just wanted to weigh in with my experience on this medication. I have believed since my June 2022 diagnosis that I would be part of the the "survivor statistics" even before I heard of PARP Inhibitors. I believe this to this day.


    Sending love, courage, and a fighting spirit to all <3


    Judith












  • 7.  RE: Zejula non brca

    Posted 10 hours ago

    @Judith thank you for your post, for sharing your PARB perspective and all the additional information. I'm thrilled that since October 2022 you have remained NED. It's something many of us aspire to!🙋‍♀️

    I had a look at the OCRA site...definitely lots of information and a good read providing information and resources from another countries perspective. I'm glad their support group has been of value to you. Have you ever participated in any of the "Teal Tea's" offered by Ovarian Cancer Canada (OCC)? Your story and perspective with those who are in attendance who perhaps aren't yet involved in OVdialogue would I'm sure be of interest to hear.

    I definitely agree with your comment that to be on a PARB is a very much an individual choice. I belong to a Facebook Lynparza group and I'm constantly reminded of how different we all are in this fight. Like Niraparib, so many women cannot manage the full dosage. I've personally been on the maximum dosage for over a year. I've experienced varying manageable side effects but feel very fortunate thus far! I have a CT later this week. I'm hoping it will show I'm still NED 🤞

    Thank you again for your insights. May you continue to be a "Superwoman" in your OV cancer fight!!!

    #Treatmentandsideeffects

    -------------------------------------------



  • 8.  RE: Zejula non brca

    Posted 2 days ago
    Hi,
    I am interested in your comment that the FDA does not prescribe Zejula for non-BRCA patients with HGSOC.  I have not been able to find anything about this other than what I describe below.  

    "FDA approval for niraparib in the maintenance setting for patients with recurrent epithelial ovarian cancer was rescinded. Currently, niraparib is approved for second-line maintenance therapy exclusively in patients harboring germline BRCA mutations (Kurnit).10 " appearing in Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review in the International Journal of Women's Health 2024:16 2239–2246.
    The FDA approval was not rescinded for first-line maintenance in non-BRCA patients with HGSOC. "Niraparib is recommended for use by the National Comprehensive Cancer Network (NCCN) guidelines and is approved by the FDA as first-line maintenance therapy in stage II–IV EOC patients, regardless of BRCA mutation or HRD-positive status, after complete (CR) or partial response (PR) to platinum-based chemotherapy.4"
    Note: the FDA rescinded Zejula only for recurrence in non-BRCA patients.

    Please share the article that you are referencing; it is difficult to keep up with the latest on this horrid disease and we do need the latest information.

    Another very interesting article provides factors that increase the chances of PFS beyond 2 years  This is encouraging for any of us that has one or more factors:

    Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study by Graybill WS, et al. Int J Gynecol Cancer 2024;34:1041–1050. doi:10.1136/ijgc-2024-005356.





  • 9.  RE: Zejula non brca

    Posted 2 days ago
    Hi,
    I am interested in your comment that the FDA does not prescribe Zejula for non-BRCA patients with HGSOC.  I have not been able to find anything about this other than what I describe below.  
    "FDA approval for niraparib in the maintenance setting for patients with recurrent epithelial ovarian cancer was rescinded. Currently, niraparib is approved for second-line maintenance therapy exclusively in patients harboring germline BRCA mutations (Kurnit).10 " appearing in Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review in the International Journal of Women's Health 2024:16 2239–2246.
    The FDA approval was not rescinded for first-line maintenance in non-BRCA patients with HGSOC. "Niraparib is recommended for use by the National Comprehensive Cancer Network (NCCN) guidelines and is approved by the FDA as first-line maintenance therapy in stage II–IV EOC patients, regardless of BRCA mutation or HRD-positive status, after complete (CR) or partial response (PR) to platinum-based chemotherapy.4"
    Note: the FDA rescinded Zejula only for recurrence in non-BRCA patients.
    Please share the article that you are referencing; it is difficult to keep up with the latest on this horrid disease and we do need the latest information.
    Another very interesting article provides factors that increase the chances of PFS beyond 2 years  This is encouraging for any of us that has one or more factors:
    Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study by Graybill WS, et al. Int J Gynecol Cancer 2024;34:1041–1050. doi:10.1136/ijgc-2024-005356.
    -------------------------------------------



  • 10.  RE: Zejula non brca

    Posted 2 days ago
    June 2025 FDA Zejula 
    Google this and all will be revealed. Thank you for your lengthy reply nonetheless. Karen


    On Sat, Aug 16, 2025 at 4:42 PM ellie via OVdialogue <Mail@onlinecommunity.ca> wrote:
    Hi, I am interested in your comment that the FDA does not prescribe Zejula for non-BRCA patients with HGSOC. I have not been able to find... -posted to the "English community" community
    Ovarian Cancer Canada

    English Community

    Post new message | Publier un nouveau message
    Re: Zejula non brca
    Reply to group | Répondre au groupe
    Aug 16, 2025 6:40 PM
    ellie
    Hi,
    I am interested in your comment that the FDA does not prescribe Zejula for non-BRCA patients with HGSOC.  I have not been able to find anything about this other than what I describe below.  
    "FDA approval for niraparib in the maintenance setting for patients with recurrent epithelial ovarian cancer was rescinded. Currently, niraparib is approved for second-line maintenance therapy exclusively in patients harboring germline BRCA mutations (Kurnit).10 " appearing in Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review in the International Journal of Women's Health 2024:16 2239–2246.
    The FDA approval was not rescinded for first-line maintenance in non-BRCA patients with HGSOC. "Niraparib is recommended for use by the National Comprehensive Cancer Network (NCCN) guidelines and is approved by the FDA as first-line maintenance therapy in stage II–IV EOC patients, regardless of BRCA mutation or HRD-positive status, after complete (CR) or partial response (PR) to platinum-based chemotherapy.4"
    Note: the FDA rescinded Zejula only for recurrence in non-BRCA patients.
    Please share the article that you are referencing; it is difficult to keep up with the latest on this horrid disease and we do need the latest information.
    Another very interesting article provides factors that increase the chances of PFS beyond 2 years  This is encouraging for any of us that has one or more factors:
    Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study by Graybill WS, et al. Int J Gynecol Cancer 2024;34:1041–1050. doi:10.1136/ijgc-2024-005356.
    -------------------------------------------
      Reply to group | Répondre au groupe   View thread | Consulter la discussion  



     
    You are receiving this notification because you are following this thread. If you do not wish to follow this, please click here.

    Update your email preferences to choose the types of email you receive

    Unsubscribe from all participation emails

    Vous recevez cette notification car vous avez suivi ce fil de discussion. Si vous ne souhaitez pas suivre ceci, veuillez cliquer ici.

    Mettez à jour vos préférences en matière de courriel pour choisir les types de courriel que vous recevez.

    Désabonnez-vous de tous les courriels aux participants






  • 11.  RE: Zejula non brca

    Posted 2 days ago

    I'm sure there will be lots of different info about these drugs, I think it's good to arm ourselves with as much research and info we can as well as talking to our service providers about evidenced based findings to make an informed decision.  Thanks for sharing all the varying articles to read through.  And thank you for sharing your personal experiences with the drugs.

    -------------------------------------------



  • 12.  RE: Zejula non brca

    Posted 2 days ago





  • 13.  RE: Zejula non brca

    Posted 2 days ago

    Very interesting.  Thanks for sharing.  Seems like slowly the data is being refined and new conclusions are being reached.  In the second article I posted, the list of factors influencing the efficacy of Zejula positively (meaning can affect PFS) includes FIGO 3 (only) HGSOC .  I expect that would be one of the discussion points between the prescriber and the patient--among the other  influencing factors such as age, # of lesions, health at diagnosis, etc.  Is complicated and for many, the risk of side effects overweigh the benefits.

    -------------------------------------------



  • 14.  RE: Zejula non brca

    Posted 2 days ago

    @ellie it's great to see that there is continued research however at the same time, a bit disparaging when yet another drug has additional limitations imposed on it relative to OV treatment. If however the risks outweigh the benefits, that is an important decision factor. I agree with your comments that there are many decision points on this and any type of treatment that are for discussion between patient and their medical team. 

    Let's just hope there's another new option around the corner 🤞

    -------------------------------------------



  • 15.  RE: Zejula non brca

    Posted 2 days ago

    @heslopk I found this yesterday and read it. Thanks 

    -------------------------------------------



  • 16.  RE: Zejula non brca

    Posted 2 days ago

    @heslopk thank you for posting the link.

    -------------------------------------------



Log in or create an account to engage on OVdialogue.